Otsuka, Lundbeck's PTSD Drug Fails to Win US FDA Panel Support
The panel of external advisers to the Food and Drug Administration voted 10-to-1 on Friday that the efficacy of the companies' brexpiprazole tablets marketed under the brand name Rexulti — in combination with sertraline — hadn't been established.
Panelists struggled to make sense of Otsuka and Lundbeck's supporting evidence, which included one successful study and one in which combining Rexulti with sertraline showed no effect on the symptoms of PTSD.
'I'm looking at these studies and I'm just not convinced the combination offers me as a clinician a new tool in the toolbox,' said Murray Raskind, a psychiatrist at the University of Washington.
The Psychopharmacologic Drugs Advisory Committee's recommendations aren't binding, but are often followed by the agency.
FDA Commissioner Marty Makary has repeatedly mentioned PTSD as a condition for which new medicines are needed, specifically for veterans.
'We owe it to that community to review some of the potential therapeutics and get a decision out without any delays,' he said in June.
The drugmakers have been seeking to broaden the approved usage of brexpiprazole, which is currently cleared for treating schizophrenia in adults and adolescents, as well as an an adjunctive therapy to antidepressants in adults with major depressive disorder.
In 2023, the FDA also approved brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer's disease. The drug was discovered by Otsuka, and the Japanese drugmaker is co-developing it with Lundbeck.
Post-traumatic stress disorder or PTSD affects about 5% of the population in the US in a given year, according to the companies. It can develop after life-threatening or traumatic events and only two medications — sertraline and paroxetine — are approved in the US to treat it. The drugs' response rates rarely exceed 60%, and fewer than 30% of patients experience full remission, according to the FDA.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
7 hours ago
- The Hindu
US may revise hormone replacement therapy warnings
US Food and Drug Administration Commissioner Marty Makary signaled Thursday that he is open to revising strict warning labels on Hormone Replacement Therapy, following testimony from experts who said the treatment's risks have long been exaggerated. HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes, vaginal discomfort, and pain during sex. But its use has plummeted in recent years amid concerns including a possible link to invasive breast cancer. Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, told AFP: "We have to revisit these topics." He argued that the framework that led to so-called "black box warnings" -- the strongest warning the FDA can require for prescription drugs -- "came from a different era." "Not only is there no clinical trial showing an increase in breast cancer mortality, but there are also other tremendous long term health benefits," Makary added. The 12 experts convened by the agency said HRT's benefits go beyond easing menopausal symptoms. They cited evidence for reduced fracture risk, improved cardiovascular and cognitive health, and fewer urinary tract infections. "Estrogen is the only well-established intervention to reduce the frequency of osteoporotic fracture in postmenopausal women, to the tune of 30 to 50 percent," said Vonda Wright, an orthopedic surgeon at the University of Central Florida. Roberta Diaz Brinton, director of the Center for Innovation in Brain Science, said her research suggests the reason two-thirds of people globally with Alzheimer's are women is not because they live slightly longer than men, but because the disease begins during the menopausal transition. "Depending upon when hormone therapy is introduced... there's a significant reduction in risk of developing Alzheimer's disease," she said. The University of Arizona researcher linked menopause to a drop in the brain's ability to metabolize glucose and a rise in protein plaque deposits. Panelists blamed the collapse in HRT use on the Women's Health Initiative (WHI), a landmark clinical trial halted in 2002 after flagging a possible increased breast cancer risk -- findings they say were misinterpreted. "Prescriptions for hormone replacement therapy plummeted in the United States, women flushed their pills down the toilet," Makary said in his opening remarks, mentioning his own mother's experience of multiple bone fractures in old age. Critics of the WHI argue it included participants well past menopause -- when risks are higher and benefits lower -- and used outdated formulations no longer common today. Label changes Still, the issue remains divisive within the medical community. HRT can be administered through various means including orally, through skin patches, or vaginally; and is given either as estrogen alone or with progesterone. The FDA's own warning label for it cites risks including endometrial cancer, breast cancer, and life-threatening blood clots. Adriane Fugh-Berman, who directs a project that promotes rational prescribing at Georgetown University, attended as an observer and criticised the lack of dissenting voices. "This was a very one-sided panel of people who are all proponents of hormone therapy and who seem to have a very poor understanding of the evidence," she told AFP. "While hormones can be a useful treatment for severe menopausal symptoms, they should not be used for chronic disease prevention," she added, noting that no randomised clinical trial -- the gold standard of evidence -- has found HRT beneficial for cognition or dementia prevention. She also said that after the WHI findings were released, hormone use fell globally -- and breast cancer rates dropped across registries tracking them. Several of the panelists had ties to companies offering menopause treatments or are affiliated with the advocacy group "Let's Talk Menopause," which receives pharmaceutical funding and campaigns to revise FDA warning labels.
Hans India
7 hours ago
- Hans India
India developing indigenous multi-stage Malaria vaccine 'AdFalciVax'
New Delhi: India has taken a major step forward in the fight against malaria with the development of a new indigenous vaccine candidate called AdFalciVax. This vaccine is being developed by the Indian Council of Medical Research (ICMR), through its institutes RMRC Bhubaneswar and the National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology's National Institute of Immunology (DBT-NII). AdFalciVax is a unique malaria vaccine that targets two key stages of Plasmodium falciparum, the parasite responsible for the deadliest form of malaria. Most existing vaccines only focus on one stage of the parasite's life cycle, but AdFalciVax is designed to provide stronger and longer-lasting protection by targeting both the human infection stage and the stage responsible for transmission through mosquitoes. In early lab testing, the vaccine has shown excellent results. Scientists believe that it could offer several benefits over current vaccines like RTS, S/AS01 and R21/Matrix-M. These include broader protection, reduced chances of the parasite escaping the immune response, and improved long-term immunity. The vaccine also remains stable for over nine months at room temperature, making it easier to store and transport, especially in tropical regions. Additionally, it uses cost-effective ingredients like alum, which is commonly used as an adjuvant in vaccines. The vaccine is currently in the preclinical stage. If everything goes as planned, it could take around seven years for the vaccine to be ready for public use. The development timeline includes manufacturing under strict safety standards, clinical trials, and regulatory approvals. One of the key innovations of AdFalciVax is that it is made using 'Lactococcus lactis', a safe and well-known bacteria used in vaccine development. Its design makes it capable of protecting individuals from getting sick while also reducing the spread of malaria within communities. The ICMR plans to offer the vaccine technology to other organisations and manufacturers under non-exclusive agreements. This means multiple companies can work on producing the vaccine, helping it reach more people faster once approved. AdFalciVax is being developed entirely in India, supporting the government's 'Make in India' initiative.
Time of India
10 hours ago
- Time of India
Why Indian farmers are chasing Matcha? Sarthak Ahuja's take on its Rs 20,000 per kg price tag goes viral
Matcha isn't just trending in your favourite cafe menu; it's also turning into green gold for Indian farmers. Recently, this was pointed out by content creator and chartered accountant for a decade, Sarthak Ahuja, who took to his Instagram and shared an insight on the same. The video has garnered over twelve thousand likes so far. In the clip, Ahuja highlighted that the popular Japanese-origin super tea is gaining ground across Indian farmlands. With the bulk of buyers, like cafes, paying between Rs 3500 and Rs 20000 per kilo, and D2C brands selling 50g packs for up to Rs 1500, matcha is quickly becoming one of the most lucrative crops on the block. But what's driving this sudden surge? And is it even sustainable? Let's understand. Why does matcha sell for Rs 20,000 per kilo in India? Matcha is an expensive tea—usually ₹20,000 per kilogram—because of the intensive labour in cultivation and processing. "While regular green tea is exposed to the sun for its entire lifetime, matcha is shaded from the sun for weeks prior to harvesting, which leads to higher chlorophyll content and a higher amino acid level of L-theanine," says Dr. Shrey Srivastava, Founder of Doctors on Duty (DOD). According to Dr. Srivastava, "Leaves are hand-harvested, steamed, dried, and finally ground into a fine powder by manual stone mills—a long, labour-intensive process. The careful manufacture produces a high-quality product containing plenty of antioxidants, flavour, and nutrients." World demand for matcha has gained momentum due to its health advantages, such as heightened metabolism, detoxification, enhanced alertness, and long-lasting energy without the crash of caffeine. It is now broadly incorporated not only in tea but also in lattes, smoothies, and sweets. Demand for Matcha cultivation has spiked in India Indian farmers have begun planting matcha owing to increased global demand and its high price in the market. 'Previously cultivated in Japan, matcha is a green tea leaf powder, which is prepared from specially cultivated green tea leaves that are high in antioxidants and health factors. Where favourable climatic conditions exist, such as in Assam, Darjeeling, and Nilgiris, Indian farmers are considering matcha as a value crop," Dr. Bhumesh Tygai, Senior Consultant-Internal Medicine, Sharda Hospital. Farming advice, better methods of cultivation, and export avenues have also contributed to this phenomenon. "Moreover, the growing consciousness of health and organic food demand domestically and abroad is prompting Indian farmers to diversify and try their hand at new crops such as matcha," he added. Why have Indian farmers also started cultivating matcha? What's the trigger? Indian farmers, particularly from states such as Assam, Nilgiris, and a portion of Himachal Pradesh, have felt the monetary value of the crop. Favourable climatic conditions and growing international demand have pushed farmers to opt for the cultivation of matcha as a high-value crop against conventional tea. "Incentives from the government, application of organic farming, and growing concern about world tea markets have also prompted Indian farmers to experiment with diversification and tap matcha's value segment," says Dr. Srivastava.
